Compare AbbVie Inc (ABBV) vs Hormel Foods Corp (HRL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Hormel Foods Corp — how do they compare? AbbVie Inc trades at $253.4 (market cap $449.91B), while Hormel Foods Corp trades at $24.48 (market cap $13.59B). The key difference: AbbVie Inc is far larger — about 33.1× Hormel Foods Corp's market cap, and Hormel Foods Corp pays the higher dividend (4.74%). Which is the better fit depends on your goals.
| ABBV | HRL | |
|---|---|---|
Market Cap | $449.91B | $13.59B |
Sector | Health | Consumer Staples |
52-Week High | $261.07 | $31.54 |
52-Week Low | $184.85 | $19.74 |
Enterprise Value | $513.38B | $15.59B |
Dividend Yield | 2.72% | 4.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.
The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.
Hormel Foods (HRL) trades at $24.70, down 1.2% on the day, with a mixed technical outlook showing bullish overall signals but bearish moving averages. The stock has consistently beaten earnings estimates in recent quarters, though net income margin has compressed to 3.82%. Recent corporate actions include steady $0.29 dividends, while the company sold its Brazilian Ceratti operations to sharpen international focus. Analyst consensus price target is $25.00, slightly above current levels.
HRL offers a stable dividend profile as a Dividend King but faces margin pressure and modest growth. Near-term upside appears limited given current valuation and mixed analyst ratings. Key risks include input cost inflation and competitive pressures in the consumer staples sector. The stock presents a defensive income opportunity rather than significant capital appreciation potential in the current environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Hormel Foods Corp
Hormel Foods is a protein-focused branded food company. Its brands include its namesake Hormel, Spam, Jennie-O, Dinty Moore, Applegate, Wholly Guacamole, and Skippy. The vast majority of the company's revenue is U.S.-based: 64% U.S. retail, 28% U.S. food service, and 8% international. By product type, in fiscal 2021, 23% of revenue was shelf-stable foods, 18% was poultry (branded and commodity), 55% was other perishable food, and 3% was other, primarily nutritional products. The company holds the number-one market position in shelf-stable meat, shelf-stable ready meals, pepperoni, natural/organic deli meat, and guacamole and the number-two position in turkey, bacon, chilled ready meals, and peanut butter.
Read more on HRL →
